These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 24175644)

  • 1. Etanercept in methotrexate-resistant JIA-related uveitis.
    Saeed MU; Raza SH; Goyal S; Cleary G; Newman WD; Chandna A
    Semin Ophthalmol; 2014 Jan; 29(1):1-3. PubMed ID: 24175644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etanercept therapy in children with treatment-resistant uveitis.
    Reiff A; Takei S; Sadeghi S; Stout A; Shaham B; Bernstein B; Gallagher K; Stout T
    Arthritis Rheum; 2001 Jun; 44(6):1411-5. PubMed ID: 11407702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis.
    Tynjälä P; Lindahl P; Honkanen V; Lahdenne P; Kotaniemi K
    Ann Rheum Dis; 2007 Apr; 66(4):548-50. PubMed ID: 17068061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry.
    Horneff G; De Bock F; Foeldvari I; Girschick HJ; Michels H; Moebius D; Schmeling H;
    Ann Rheum Dis; 2009 Apr; 68(4):519-25. PubMed ID: 18413440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of long-term etanercept in the treatment of methotrexate-refractory polyarticular-course juvenile idiopathic arthritis in Japan.
    Mori M; Takei S; Imagawa T; Imanaka H; Nerome Y; Higuchi R; Kawano Y; Yokota S; Sugiyama N; Yuasa H; Fletcher T; Wajdula JS
    Mod Rheumatol; 2012 Sep; 22(5):720-6. PubMed ID: 22212889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.
    Quartier P; Taupin P; Bourdeaut F; Lemelle I; Pillet P; Bost M; Sibilia J; Koné-Paut I; Gandon-Laloum S; LeBideau M; Bader-Meunier B; Mouy R; Debré M; Landais P; Prieur AM
    Arthritis Rheum; 2003 Apr; 48(4):1093-101. PubMed ID: 12687553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry.
    Foeldvari I; Becker I; Horneff G
    Arthritis Care Res (Hoboken); 2015 Nov; 67(11):1529-35. PubMed ID: 25988824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etanercept and uveitis in patients with juvenile idiopathic arthritis.
    Schmeling H; Horneff G
    Rheumatology (Oxford); 2005 Aug; 44(8):1008-11. PubMed ID: 15855187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis.
    Smith JA; Thompson DJ; Whitcup SM; Suhler E; Clarke G; Smith S; Robinson M; Kim J; Barron KS
    Arthritis Rheum; 2005 Feb; 53(1):18-23. PubMed ID: 15696578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients.
    Southwood TR; Foster HE; Davidson JE; Hyrich KL; Cotter CB; Wedderburn LR; Hull RG; Venning HE; Rahman JK; Cummins CL;
    Rheumatology (Oxford); 2011 Jan; 50(1):189-95. PubMed ID: 21047801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
    Otten MH; Prince FH; Armbrust W; ten Cate R; Hoppenreijs EP; Twilt M; Koopman-Keemink Y; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
    JAMA; 2011 Dec; 306(21):2340-7. PubMed ID: 22056397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register.
    Prince FH; Twilt M; ten Cate R; van Rossum MA; Armbrust W; Hoppenreijs EP; van Santen-Hoeufft M; Koopman-Keemink Y; Wulffraat NM; van Suijlekom-Smit LW
    Ann Rheum Dis; 2009 May; 68(5):635-41. PubMed ID: 18413443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept.
    van Dijken TD; Vastert SJ; Gerloni VM; Pontikaki I; Linnemann K; Girschick H; Armbrust W; Minden K; Prince FH; Kokke FT; Nieuwenhuis EE; Horneff G; Wulffraat NM
    J Rheumatol; 2011 Jul; 38(7):1441-6. PubMed ID: 21459936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey.
    Foeldvari I; Nielsen S; Kümmerle-Deschner J; Espada G; Horneff G; Bica B; Olivieri AN; Wierk A; Saurenmann RK
    J Rheumatol; 2007 May; 34(5):1146-50. PubMed ID: 17343318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis.
    Giannini EH; Ilowite NT; Lovell DJ; Wallace CA; Rabinovich CE; Reiff A; Higgins G; Gottlieb B; Singer NG; Chon Y; Lin SL; Baumgartner SW;
    Arthritis Rheum; 2009 Sep; 60(9):2794-804. PubMed ID: 19714630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.
    Weinblatt ME; Kremer JM; Bankhurst AD; Bulpitt KJ; Fleischmann RM; Fox RI; Jackson CG; Lange M; Burge DJ
    N Engl J Med; 1999 Jan; 340(4):253-9. PubMed ID: 9920948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy.
    Aikawa NE; França IL; Ribeiro AC; Sallum AM; Bonfa E; Silva CA
    Vaccine; 2015 Jan; 33(5):604-9. PubMed ID: 25554240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching the therapy from etanercept to infliximab in a child with rheumatoid factor positive polyarticular juvenile idiopathic arthritis.
    Nerome Y; Imanaka H; Nonaka Y; Takei S
    Mod Rheumatol; 2007; 17(6):526-8. PubMed ID: 18084710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Anti-TNFalpha treatment of juvenile uveitis].
    Fledelius HC; Nielsen SM; Nissen KR; Pedersen FK; Zak MS
    Ugeskr Laeger; 2007 Apr; 169(14):1309-12. PubMed ID: 17437693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgery for hypotony in patients with juvenile idiopathic arthritis-associated uveitis.
    Yu EN; Paredes I; Foster CS
    Ocul Immunol Inflamm; 2007; 15(1):11-7. PubMed ID: 17365801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.